Investigate the feasibility of altering cancer drug sensitivity through modulation of AHR activity

• Project/Area Number: 24K10327
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50010:Tumor biology-related
• Research Institution: University of Tsukuba
• Principal Investigator: Louphrasitthiphol Pakavarin 筑波大学, 医学医療系, 客員研究員 (60897081)
• Project Period (FY): 2024-04-01 – 2027-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2026: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000); Fiscal Year 2025: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2024: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
• Keywords: AHR / Acquired drug resistance / Transcriptomics

Outline of Research at the Start

To overcome AHR elicited drug resistance, we will unbiasedly investigate how diets and the derivative compounds influence local AHR activity using muti-omics approaches (RNA-seq, metabolomics, proteomic and microbiome) at a whole organism level with organ specific resolution.